PMID- 36792084
OWN - NLM
STAT- MEDLINE
DCOM- 20230217
LR  - 20230405
IS  - 1999-6187 (Electronic)
IS  - 1009-3419 (Print)
IS  - 1009-3419 (Linking)
VI  - 26
IP  - 1
DP  - 2023 Jan 20
TI  - [Lung Squamous Cell Carcinoma with EML4-ALK Fusion and TP53 Co-mutation 
Treated 
      with Ensartinib: A Case Report and Literature Review].
PG  - 78-82
LID - 10.3779/j.issn.1009-3419.2023.106.03 [doi]
AB  - Lung squamous cell carcinoma (LSCC) accounts for approximately 30% of non-small 
      cell lung cancer (NSCLC) cases and is the second most common histological type of 
      lung cancer. Anaplastic lymphoma kinase (ALK)-positive NSCLC accounts for only 
      2%-5% of all NSCLC cases, and is almost exclusively detected in patients with 
      lung adenocarcinoma. Thus, ALK testing is not routinely performed in the LSCC 
      population, and the efficacy of such treatment for ALK-rearranged LSCC remains 
      unknown. Echinoderm microtubule associated protein like 4 (EML4)-ALK (V1) and 
      TP53 co-mutations were identified by next generation sequencing (NGS) in this 
      patient with advanced LSCC. On December 3, 2020, Ensatinib was taken orally and 
      the efficacy was evaluated as partial response (PR). The progression-free 
      survival (PFS) was 19 months. When the disease progressed, the medication was 
      changed to Loratinib. To our knowledge, Enshatinib created the longest PFS of 
      ALK-mutant LSCC patients treated with targeted therapy since literature review. 
      Herein, we described one case treated by Enshatinib involving a patient with both 
      EML4-ALK and TP53 positive LSCC, and the relevant literatures were reviewed for 
      discussing the treatment of this rare disease.
.
FAU - Lv, Donglai
AU  - Lv D
AD  - Department of Medical Oncology, 901 Hospital of Joint Logistics Support Force of 
      People Liberation Army, Hefei 230031, China.
FAU - Xu, Chunwei
AU  - Xu C
AD  - Department of Respiratory and Critical Care Medicine, Jinling Hospital, Nanjing 
      University School of Medicine, Nanjing 210002, China.
FAU - Wang, Chong
AU  - Wang C
AD  - Department of Medical Oncology, 901 Hospital of Joint Logistics Support Force of 
      People Liberation Army, Hefei 230031, China.
FAU - Sang, Qiuju
AU  - Sang Q
AD  - Department of Medical Oncology, 901 Hospital of Joint Logistics Support Force of 
      People Liberation Army, Hefei 230031, China.
LA  - chi
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
RN  - SMA5ZS5B22 (ensartinib)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - 0 (Cytoskeletal Proteins)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 0 (EML4-ALK fusion protein, human)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - *Lung Neoplasms/drug therapy/genetics/pathology
MH  - Anaplastic Lymphoma Kinase/genetics/metabolism
MH  - *Carcinoma, Squamous Cell/drug therapy/genetics
MH  - Mutation
MH  - Cytoskeletal Proteins/genetics
MH  - Lung/pathology
MH  - Oncogene Proteins, Fusion/genetics
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Tumor Suppressor Protein p53/genetics
PMC - PMC9987096
OTO - NOTNLM
OT  - ALK fusion gene
OT  - Ensartinib
OT  - Lorlatinib
OT  - Lung neoplasms
OT  - Tp53
EDAT- 2023/02/16 06:00
MHDA- 2023/02/18 06:00
PMCR- 2023/01/20
CRDT- 2023/02/15 20:23
PHST- 2023/02/15 20:23 [entrez]
PHST- 2023/02/16 06:00 [pubmed]
PHST- 2023/02/18 06:00 [medline]
PHST- 2023/01/20 00:00 [pmc-release]
AID - 10.3779/j.issn.1009-3419.2023.106.03 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2023 Jan 20;26(1):78-82. doi: 
      10.3779/j.issn.1009-3419.2023.106.03.